This winter solstice, I reflect on moving from darkness to light
How I've worked to keep hope alive throughout my CF and transplant journey Written by Lara Govendo I’m no stranger to frigid temperatures and dark days, as it often feels like the tundra here in Vermont. As we approach the winter solstice , I’m reflecting on the symbolism of letting the light in after dark times. I was born in the wee hours of Dec. 22, just as we in the northern hemisphere are emerging from the darkest day of the year and tiptoeing toward lighter days. My jo


Inhaled therapy ETD001 well tolerated in healthy volunteers
Phase 1 trial data also indicate prolonged exposure of drug to lungs Written by Steve Bryson, PhD | ETD001, Enterprise Therapeutics ’ inhaled investigational therapy to improve mucus clearance in people with cystic fibrosis (CF) — regardless of the underlying CF-causing mutation — was well tolerated in healthy individuals at doses higher than those predicted to be therapeutic, a study showed. The now-complete Phase 1 safety study (NCT04926701) also showed the inhaled drug


Genetic Counseling and Neonatal Screening for Cystic Fibrosis: An Assessment of the Communication Process
Ciske, David J. Haavisto, Amy MD Laxova, Anita Rock, Lan ZengMichael MD Farrell, Philip M. MD, PhD Author information From the Department of Pediatrics, University of Wisconsin, Madison, Wisconsin.Received for publication Dec 14, 999; accepted Jul 31, 2000. Reprint requests to (P.M.F.) University of Wisconsin Medical School, Room 1217 Medical Sciences Center, 1300 University Ave, Madison, WI 53706. E-mail: pmfarrel@facstaff.wisc.edu Pediatrics 107(4):p 699-705, April 2001 AB


Lung structure abnormalities seen on CT predict success with Trikafta
New findings explain wide variability in therapy's effects among CF patients by Marisa Wexler, MS People with cystic fibrosis (CF) who have certain lung structure abnormalities — ones visible on CT scans — are more likely than those with other issues also seen via imaging to experience improvements in lung function after starting treatment with Trikafta . That’s according to the results of a new analysis that used imaging scans and artificial intelligence (AI) tools to asse


Kaftrio success leaves some CF patients feeling forgotten
Adults not eligible for approved therapy report conflicting emotions by Steve Bryson, PhD | Adults with cystic fibrosis (CF) who are not eligible for Kaftrio therapy reported feeling forgotten in both the media and research, with conflicting emotions about those who do benefit from the approved treatment, according to a new interview-based study by researchers in the U.K. Study participants noted that they also felt a loss of hope when they realized they weren’t eligible f








































